Trevena, Inc. (TRVN)

Market Cap	959.00 -99.6%
Revenue (ttm)	546.00K -83.0%
Net Income	-34.04M
EPS	-42.72
Shares Out	958.79K
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	109
Open	0.0010
Previous Close	n/a
Day's Range	0.0010 - 0.0010
52-Week Range	0.0010 - 1.5010
Beta	-0.41
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 21, 2026

About Trevena

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managin...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 23
• Stock Exchange: OTCMKTS
• Ticker Symbol: TRVN

Financial Performance

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 22, 2026

Data Sources Report a data error